Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
SEATTLE, Sept. 29, 2017 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO, will be a featured presenter at The MicroCap Conference on Thursday October 5, 2017 at 12:30 PM Eastern Time. The conference is being held at the Essex House in New York City. Mr. Guse will also be available for one-on-one meetings with the investment community.
About Atossa Genetics
Atossa Genetics Inc., is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
866 893-4927
[email protected]
Investor Relations Contact
Scott Gordon
CorProminence LLC
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516.222.2560
[email protected]
